The swine division of Boehringer Ingelheim Vetmedica, Inc., traces its U.S. roots back to the early 1900s when hog cholera was the devastating disease of the period for hog producers. Over the last 100 years, and after several name changes and acquisitions – including Fermenta Animal Health and NOBL Laboratories, Sioux Center, Iowa, and its Swine Health Management Center, Ames, Iowa – the swine division has been on the cutting edge of swine health innovation.

• Innovator in single-dose injectable and single-dose oral swine vaccines
• First modified-live vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS)
• First avirulent-live vaccine against Salmonella choleraesuis
• First single-dose Mycoplasma hyopneumoniae vaccine
• First avirulent-live Lawsonia intracellularis vaccine for Porcine Proliferative Enteropathy (PPE, ileitis)
• Market-leading vaccines for Porcine Circovirus Type 2 and Mycoplasma hyopneumoniae 

Today with nearly 18 swine vaccines and other health products in its swine portfolio, state-of-the-art manufacturing and diagnostic facilities, and industry-leading research programs, Boehringer Ingelheim Vetmedica, Inc., is one of the premiere global swine health companies. More importantly, the swine division continues to seek effective solutions to costly swine health and production problems that challenge the swine industry.